Compare AbCellera Biologics Inc (ABCL) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Adaptive Biotechnologies Corp — how do they compare? AbCellera Biologics Inc trades at $8.93 (market cap $2.85B), while Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ADPT | |
|---|---|---|
Market Cap | $2.85B | $4.05B |
Sector | Health | Health |
52-Week High | $9.76 | $25.45 |
52-Week Low | $2.78 | $12.30 |
Enterprise Value | $2.45B | $4.12B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
